pharma · Alzheimer Disease · Pulmonary Fibrosis
Shanghai University of
Shanghai University of Traditional Chinese Medicine
Shanghai University of is a pharma organization headquartered in CN. Primary therapeutic focus areas include Alzheimer Disease, Pulmonary Fibrosis, RESPIRATORY SYNCYTIAL VIRUS INFECTIONS, Chemotherapy, Adjuvant, Neoplasm
Shanghai, China, CN HQ
6 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Shanghai, China, CN
- Employees
- 6
- Programs
- 24
- Drugs
- 33
- Patents
- 0
Furmonertinib
Phase 2 · small molecule · Lung Adenocarcinoma Stage III
Furmonertinib for Lung Adenocarcinoma Stage III is a Phase 2 program (small_molecule) at Shanghai University of Traditional Chinese Medicine with 1 ClinicalTrials.gov record(s).
Internal code LungMate-012
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Shanghai University of Traditional Chinese Medicine
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Lung Adenocarcinoma Stage III
- Status
- active
- Trials
- 1